Statin treatment for people with compensated cirrhosis
Statin Therapy for patients with compensated Cirrhosis
This project will see if taking statin medicines helps people with compensated cirrhosis avoid serious liver complications.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11171660 on NIH RePORTER |
What this research studies
If you have compensated cirrhosis, researchers at the University of Michigan and partner centers will invite you to join a long-term group where they collect medical tests, liver fibrosis measures, blood markers, and regular questionnaires about symptoms and quality of life. Some participants will receive statin therapy as part of the study and clinicians will track who develops liver decompensation or hepatocellular carcinoma over time. The team will combine patient-reported outcomes with clinical and lab data to build better risk models and understand whether statins change outcomes. The effort is a prospective, multicenter approach aimed at producing real-world evidence beyond past observational reports.
Who could benefit from this research
Good fit: Adults with compensated cirrhosis who have not had prior decompensation and who are medically able to take statins are the ideal candidates.
Not a fit: People with decompensated cirrhosis, advanced liver failure, or contraindications to statins are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, statin therapy could lower the risk of liver decompensation and liver cancer and improve symptoms and survival for people with compensated cirrhosis.
How similar studies have performed: Observational studies have linked statin use to lower rates of cirrhosis complications, but prospective or randomized trials confirming benefit are not yet available.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Tapper, Elliot — University of Michigan at Ann Arbor
- Study coordinator: Tapper, Elliot
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.